Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hafalia
April J.a. Hafalia, Daly City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080241158 | Human taste-specific receptor TIR3 - The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC. | 10-02-2008 |
April J. A. Hafalia, Santa Clara, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100099617 | Secreted proteins - The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP. | 04-22-2010 |
April J. A. Hafalia, Dale City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090274680 | Human Phospholipases - The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME. | 11-05-2009 |
April J. A. Hafalia, Daly City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120014937 | Human Beta-Adrenergic receptor kinase polypeptide and methods - Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP. | 01-19-2012 |